Edwards Lifesciences Corporation
EW
Peringkat dalam Saham
#485
Edwards Lifesciences Corporation is a global medical technology firm... Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.
Harga Saham
$86.95
Kapitalisasi Pasar
$50.12B
Perubahan (1 hari)
0.57%
Perubahan (1 tahun)
16.49%
Negara
US
Perdagangan Edwards Lifesciences Corporation (EW)
Kategori
Healthcare
Margin Operasi untuk Edwards Lifesciences Corporation (EW)
Margin Operasi per October 2026 TTM: 28.09%
Menurut laporan keuangan dan harga saham terbaru dari Edwards Lifesciences Corporation, margin operasi saat ini (TTM) adalah 28.09%. Pada akhir 2024, margin operasi perusahaan adalah 25.35%.
Riwayat margin operasi untuk Edwards Lifesciences Corporation dari 2000 hingga 2026
Margin Operasi pada akhir setiap tahun
| Tahun | Margin Operasi | Mengubah |
|---|---|---|
| 2026 (TTM) | 28.09% | -2,630.63% |
| 2025 | -1.11% | -104.38% |
| 2024 | 25.35% | -11.02% |
| 2023 | 28.49% | -9.93% |
| 2022 | 31.63% | 2.76% |
| 2021 | 30.78% | 4.16% |
| 2020 | 29.55% | 7.26% |
| 2019 | 27.55% | -6.10% |
| 2018 | 29.34% | -0.20% |
| 2017 | 29.40% | 6.83% |
| 2016 | 27.52% | 19.19% |
| 2015 | 23.09% | 10.11% |
| 2014 | 20.97% | -0.94% |
| 2013 | 21.17% | 1.39% |
| 2012 | 20.88% | 6.48% |
| 2011 | 19.61% | 0.46% |
| 2010 | 19.52% | 10.72% |
| 2009 | 17.63% | 4.38% |
| 2008 | 16.89% | 8.76% |
| 2007 | 15.53% | -1.52% |
| 2006 | 15.77% | -10.40% |
| 2005 | 17.60% | 6.15% |
| 2004 | 16.58% | 3.11% |
| 2003 | 16.08% | 117.30% |
| 2002 | 7.40% | 113.26% |
| 2001 | 3.47% | -70.64% |
| 2000 | 11.82% | 0.00% |
Margin Operasi untuk perusahaan sejenis atau pesaing
| Perusahaan | Margin Operasi | Perbedaan Margin Operasi | Negara |
|---|---|---|---|
| 17.03% | -99.39% |
US
|
|
| 17.86% | -99.36% |
IE
|
|
| 22.03% | -99.22% |
US
|
|
| 21.46% | -99.24% |
US
|
|
| 0.00% | - |
DE
|
Apa itu Margin Operasi perusahaan?
Margin Operasi adalah indikator utama untuk menilai profitabilitas suatu perusahaan. Margin Operasi yang lebih tinggi umumnya lebih baik karena menunjukkan bahwa perusahaan mampu menjual produk atau layanan mereka dengan harga yang jauh lebih tinggi daripada biaya produksinya. Margin Operasi dihitung dengan membagi laba perusahaan dengan pendapatannya.